COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Ventricular Arrhythmias in Uremic Cardiomyopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01856400
Recruitment Status : Completed
First Posted : May 17, 2013
Last Update Posted : February 3, 2014
Icahn School of Medicine at Mount Sinai
Information provided by (Responsible Party):
Suzanne El-Sayegh, Northwell Health

Brief Summary:
There is a certain gene called sarcoplasmic reticulum gene (SERCA2a), which is found in heart muscle. This gene is also found in blood vessels and skin tissue. When active this gene builds a crucial protein inside the heart muscle called SERCA2a protein. This is responsible for regulating calcium levels inside your heart muscle. When this gene is not activated, studies have shown that it can lead to abnormal electrical currents in the heart that can lead to death. The investigators are conducting this study to prove that SERCA2a gene is inactive in patients with kidney disease. Scientists found that patient at risk for abnormal electrical currents in the heart can be tested by what they called "microvolt Twave alternans." This is a very delicate machine much more sensitive than a regular electrocardiogram that you do at the cardiology office.

Condition or disease

Detailed Description:
This study will test the hypothesis that patients with uremic cardiomyopathy have reduced levels of SERCA2a protein compared to those with normal kidney function. We propose that such a correlation will provide convincing evidence that these patients,have a defective redistribution in intracellular calcium handling as an explanation for their increase risk in sudden cardiac death an fatal arrhythmias. To achieve our specific aims: 1) we will screen patients with end stage renal disease (ESRD) going for certain vascular procedures. 2) obtain an echocardiogram on these patients including only those with isolated diastolic dysfunction or LVH. 3) Patients who has diastolic dysfunction or LVH will be assessed for underlying microvolt (TWA) 4) vessel and skin tissue on these patients will be collected for SERCA2a quantification.

Layout table for study information
Study Type : Observational
Actual Enrollment : 36 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Understanding the Molecular Basis of Ventricular Arrhythmias in Uremic Cardiomyopathy
Study Start Date : January 2010
Actual Primary Completion Date : August 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Molecular basis of ventricular arrythmias in uremic cardiomyopathy [ Time Frame: At time of surgery ]
    To assess the expression of SERCA2a gene expression in Uremic Cardiomyopathy patients to see if the degree of expression is implicated in ventricular arrythmias

Biospecimen Retention:   Samples With DNA
blood vessel tissue sample

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Hemodialysis Patients Uremic Patients Diastolic dysfunction

Inclusion Criteria:

  • age 18 years or older
  • Patients with stage 5 CKD or ESRD and those with normal CKD will be considered as possible candidates if admitted for one of the following vascular procedures
  • coronary artery bypass grafting, or vascular bypass surgery, or arteriovenous fistula creation, or arteriovenous graft surgery.
  • The aforementioned patients will be included if they have LVH or diastolic dysfunction and a normal LVEF on echocardiogram within one year of their scheduled surgery.

Exclusion Criteria:

  1. Age less than 18 ;
  2. Pregnancy;
  3. Dilated cardiomyopathy;
  4. left ventricular ejection fraction (LVEF) less than or equal to 50%;
  5. Patients on digoxin.
  6. antiarrhytmic medications;
  7. baseline electrolyte abnormalities;
  8. Atrial fibrillation;
  9. Bundle branch block

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01856400

Layout table for location information
United States, New York
Staten Island University Hospital
Staten Island, New York, United States, 10305
Sponsors and Collaborators
Northwell Health
Icahn School of Medicine at Mount Sinai
Layout table for investigator information
Principal Investigator: Suzanne El-Sayegh, MD SIUH
Layout table for additonal information
Responsible Party: Suzanne El-Sayegh, M.D., Northwell Health Identifier: NCT01856400    
Other Study ID Numbers: 09-053
First Posted: May 17, 2013    Key Record Dates
Last Update Posted: February 3, 2014
Last Verified: January 2014
Keywords provided by Suzanne El-Sayegh, Northwell Health:
ventricular arrythmias
Chronic Kidney Disease
microvolt T wave alternans
Additional relevant MeSH terms:
Layout table for MeSH terms
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes